Please use this identifier to cite or link to this item:
http://hdl.handle.net/10397/6251
| Title: | Deprivation of arginine by recombinant human arginase in prostate cancer cells | Authors: | Hsueh, EC Knebel, SM Lo, WHT Leung, TYC Cheng, PNM Hsueh, CT |
Issue Date: | 30-Apr-2012 | Source: | Journal of hematology & oncology, 30 Apr. 2012, v. 5, 17, p. 1-6 | Abstract: | Background: Recombinant human arginase (rhArg) has been developed for arginine deprivation therapy in cancer, and is currently under clinical investigation. During pre-clinical evaluation, rhArg has exhibited significant anti-proliferative activity in cancer cells deficient in the expression of ornithine carbamoyl transferase (OCT). Interestingly, a variety of cancer cells such as melanoma and prostate cancer deficient in argininosuccinate synthetase (ASS) are sensitive to arginine deprivation by arginine deiminase. In this study, we investigated levels of gene expression of OCT and ASS, and the effects of rhArg in human prostate cancer cells: LNCaP (androgen-dependent), PC-3 and DU-145 (both androgen-independent). Results: Quantitative real-time PCR showed minimal to absent gene expression of OCT, but ample expression of ASS expression in all 3 cell lines. Cell viability assay after 72-h exposure of rhArg showed all 3 lines had half maximal inhibitory concentration less than or equal to 0.02 U/ml. Addition of ornithine to cell culture media failed to rescue these cells from rhArg-mediated cytotoxicity. Decreased phosphorylation of 4E-BP1, a downstream effector of mammalian target of rapamycin (mTOR), was noted in DU-145 and PC-3 after exposure to rhArg. Moreover, there was no significant apoptosis induction after arginine deprivation by rhArg in all 3 prostate cancer cell lines. Conclusion: rhArg causes significant cytotoxicity in LNCaP, DU-145 and PC-3 prostate cancer cells which all demonstrate decreased OCT expression. Inhibition of mTOR manifested by hypophosphorylation of 4E-BP1 suggests autophagy is involved as alternative cell death mechanism. rhArg demonstrates a promising novel agent for prostate cancer treatment. |
Keywords: | Arginase Argininosuccinate synthetase Autophagy Mammalian target of rapamycin Ornithine carbamoyl transferase Prostate cancer |
Publisher: | BioMed Central Ltd. | Journal: | Journal of hematology & oncology | ISSN: | 1756-8722 | DOI: | 10.1186/1756-8722-5-17 | Rights: | © 2012 Hsueh et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
| Appears in Collections: | Journal/Magazine Article |
Files in This Item:
| File | Description | Size | Format | |
|---|---|---|---|---|
| Hsueh_Arginine_Recombinant_Cancer.pdf | 516.75 kB | Adobe PDF | View/Open |
Access
View full-text via PolyU eLinks 
Page views
95
Last Week
1
1
Last month
Citations as of Jun 11, 2023
Downloads
117
Citations as of Jun 11, 2023
SCOPUSTM
Citations
66
Last Week
0
0
Last month
0
0
Citations as of Jun 8, 2023
WEB OF SCIENCETM
Citations
63
Last Week
0
0
Last month
0
0
Citations as of Jun 8, 2023
Google ScholarTM
Check
Altmetric
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.